369 related articles for article (PubMed ID: 24099875)
1. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
[TBL] [Abstract][Full Text] [Related]
2. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
[TBL] [Abstract][Full Text] [Related]
3. Effective chikungunya virus-like particle vaccine produced in insect cells.
Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
[TBL] [Abstract][Full Text] [Related]
4. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
Front Immunol; 2021; 12():655743. PubMed ID: 33868299
[TBL] [Abstract][Full Text] [Related]
5. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
Arévalo MT; Huang Y; Jones CA; Ross TM
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260
[TBL] [Abstract][Full Text] [Related]
8. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
Front Immunol; 2020; 11():591885. PubMed ID: 33224148
[TBL] [Abstract][Full Text] [Related]
10. Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus.
Basu R; Zhai L; Rosso B; Tumban E
Vaccine; 2020 Mar; 38(11):2542-2550. PubMed ID: 32044164
[TBL] [Abstract][Full Text] [Related]
11. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.
van den Doel P; Volz A; Roose JM; Sewbalaksing VD; Pijlman GP; van Middelkoop I; Duiverman V; van de Wetering E; Sutter G; Osterhaus AD; Martina BE
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3101. PubMed ID: 25188230
[TBL] [Abstract][Full Text] [Related]
12. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
[TBL] [Abstract][Full Text] [Related]
13. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
[TBL] [Abstract][Full Text] [Related]
14. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.
Partidos CD; Paykel J; Weger J; Borland EM; Powers AM; Seymour R; Weaver SC; Stinchcomb DT; Osorio JE
Vaccine; 2012 Jun; 30(31):4638-43. PubMed ID: 22583812
[TBL] [Abstract][Full Text] [Related]
15. Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells.
Metz SW; Pijlman GP
Methods Mol Biol; 2016; 1426():297-309. PubMed ID: 27233282
[TBL] [Abstract][Full Text] [Related]
16. Superior protection conferred by inactivated whole virus vaccine over subunit and DNA vaccines against salmonid alphavirus infection in Atlantic salmon (Salmo salar L.).
Xu C; Mutoloki S; Evensen Ø
Vaccine; 2012 Jun; 30(26):3918-28. PubMed ID: 22504037
[TBL] [Abstract][Full Text] [Related]
17. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
[TBL] [Abstract][Full Text] [Related]
18. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
Front Immunol; 2020; 11():304. PubMed ID: 32194557
[TBL] [Abstract][Full Text] [Related]
19. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.
Selvarajah S; Sexton NR; Kahle KM; Fong RH; Mattia KA; Gardner J; Lu K; Liss NM; Salvador B; Tucker DF; Barnes T; Mabila M; Zhou X; Rossini G; Rucker JB; Sanders DA; Suhrbier A; Sambri V; Michault A; Muench MO; Doranz BJ; Simmons G
PLoS Negl Trop Dis; 2013; 7(9):e2423. PubMed ID: 24069479
[TBL] [Abstract][Full Text] [Related]
20. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.
Partidos CD; Weger J; Brewoo J; Seymour R; Borland EM; Ledermann JP; Powers AM; Weaver SC; Stinchcomb DT; Osorio JE
Vaccine; 2011 Apr; 29(16):3067-73. PubMed ID: 21300099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
